Literature DB >> 10741195

Transpelvic rectus abdominis flap for perineal reconstruction following abdominal perineal resection with en bloc partial cystectomy and prostatectomy for locally advanced rectal cancer.

B S Ooi1, D C Nyam, C Cheng, K C Tan, W H Koo, K S Lee.   

Abstract

We report a case of locally advanced carcinoma of the rectum invading the bladder and prostate in a young man treated initially with neoadjuvant chemoradiotherapy. This was followed by an en bloc resection of the tumour, partial cystectomy and prostatectomy and an abdominal perineal resection. The urinary bladder was reconstructed and a new bladder neck reimplanted into the proximal urethra where the sphincter had been preserved. There was extensive radiation changes to the perineal skin where a wide excision had been performed. The pelvic defect was reconstructed with a pedicled transpelvic rectus abdominis myocutaneous flap. The patient recovered uneventfully and remains well with no clinical evidence of recurrence 18 months post-operatively. In very selected cases there is a definite role for neoadjuvant therapy and enbloc resection of the tumour followed by reconstruction of the perineum.

Entities:  

Mesh:

Year:  1999        PMID: 10741195

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  3 in total

1.  A hundred patients with vertical rectus abdominis myocutaneous (VRAM) flap for pelvic reconstruction after total pelvic exenteration.

Authors:  R E Horch; W Hohenberger; A Eweida; U Kneser; K Weber; A Arkudas; S Merkel; J Göhl; J P Beier
Journal:  Int J Colorectal Dis       Date:  2014-04-22       Impact factor: 2.571

Review 2.  Rectal cancer and Fournier's gangrene - current knowledge and therapeutic options.

Authors:  Tomislav Bruketa; Matea Majerovic; Goran Augustin
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

3.  Scrotal and perineal reconstruction.

Authors:  Nho V Tran
Journal:  Semin Plast Surg       Date:  2011-08       Impact factor: 2.314

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.